Monteluster sodium is an effective oral selective antagonist of leukotrienes receptor, which can specifically inhibit cysteamine leukotrienes receptor. It was successfully developed by Merck of Germany and listed in Canada, Finland and Mexico in 1997. For adults and children asthma prevention and treatment for a long time, including the prevention of asthma symptoms of day and night, sensitive to aspirin treatment of asthma and to prevent movement of bronchoconstriction, can also be used to alleviate the age of 15 and 15 years of age or older patients resistant to other treatment is invalid or not seasonal allergic rhinitis symptoms.